• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Securities Litigation Reform Act

Securities Litigation Reform Act

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

    Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

  2. Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

    Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine

  3. Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

    Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting

  4. Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq™, its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of ...

    Sorrento Therapeutics Announces Three Preclinical Poster Presentations on Cynviloq™, its Novel Antibody Drug Conjugate Linker Technology and c-Met/EGFR Bispecific ADC at the 106th Annual Meeting of the American Association for Cancer Research

  5. Alpha Natural Resources Plans To Restore Compliance With NYSE Minimum Share Price Listing Standard

    Alpha Natural Resources Plans To Restore Compliance With NYSE Minimum Share Price Listing Standard

  6. National MI Comments on New Private MI Eligibility Standards

    National MI Comments on New Private MI Eligibility Standards

  7. China Zenix Auto International Announces Fourth Quarter and 2014 Financial Results

    China Zenix Auto International Announces Fourth Quarter and 2014 Financial Results

  8. Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting

    Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting

  9. A. M. Castle & Co. Appoints Steven Scheinkman as President and Chief Executive Officer

    A. M. Castle & Co. Appoints Steven Scheinkman as President and Chief Executive Officer

  10. Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients

    Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.